Cargando…
A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression
Immune-checkpoint blockade (ICB) therapy has changed the clinical outcome of many types of aggressive tumors, but there still remain many cancer patients that do not respond to these treatments. There is an unmet need to develop a feasible clinical therapeutic platform to increase the rate of respon...
Autores principales: | Meraviglia-Crivelli, Daniel, Villanueva, Helena, Menon, Ashwathi Puravankara, Zheleva, Angelina, Moreno, Beatriz, Villalba-Esparza, María, Pastor, Fernando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379514/ https://www.ncbi.nlm.nih.gov/pubmed/35991316 http://dx.doi.org/10.1016/j.omtn.2022.07.017 |
Ejemplares similares
-
IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction
por: Meraviglia-Crivelli, Daniel, et al.
Publicado: (2022) -
Modulating T Cell Responses by Targeting CD3
por: Menon, Ashwathi Puravankara, et al.
Publicado: (2023) -
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?
por: Sola, Mayte, et al.
Publicado: (2020) -
ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity
por: Soldevilla, Mario Martínez, et al.
Publicado: (2019) -
Aptamer-iRNAs as Therapeutics for Cancer Treatment
por: Soldevilla, Mario M., et al.
Publicado: (2018)